---
title: "GEMPHARMATECH: Overseas business focuses on the delivery of efficacy reports, \"reciprocal tariffs\" have little impact on the company"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/234917060.md"
description: "GEMPHARMATECH is accelerating its internationalization strategy, expanding into overseas markets, and building a sales network covering the Asia-Pacific, Europe, and the United States. The company's overseas business mainly revolves around the delivery of efficacy reports, which is less affected by \"countervailing tariffs.\" GEMPHARMATECH is also actively constructing overseas facilities to enhance market competitiveness and respond to market risks, laying a foundation for long-term development"
datetime: "2025-04-08T02:28:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/234917060.md)
  - [en](https://longbridge.com/en/news/234917060.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/234917060.md)
---

# GEMPHARMATECH: Overseas business focuses on the delivery of efficacy reports, "reciprocal tariffs" have little impact on the company

According to GEMPHARMATECH, the company is continuously advancing its internationalization strategy, accelerating the pace of expansion into overseas markets, and successfully building an overseas sales network covering multiple countries and regions in the Asia-Pacific, Europe, and the Americas. The main customers are relatively evenly distributed across North America, Europe, and the Asia-Pacific regions. At the same time, in the aforementioned non-core areas, the company has effectively enhanced the coverage and expansion speed of overseas markets through agents. GEMPHARMATECH stated that currently, the company's overseas business mainly revolves around the delivery of efficacy reports, and due to the uniqueness of its business structure, it is less sensitive to "equivalent tariffs." Meanwhile, GEMPHARMATECH is actively deploying the construction of overseas facilities. Through this initiative, the company aims to enhance its market competitiveness and strengthen its ability to respond to market risks, laying a solid foundation for the company's long-term development

### Related Stocks

- [688046.CN](https://longbridge.com/en/quote/688046.CN.md)

## Related News & Research

- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)
- [Phase 3-ready cancer biotech Parabilis Medicines files for a $100 million IPO](https://longbridge.com/en/news/286972125.md)
- [09:35 ETOpen Medicine Launches Ahead of ASCO, Introducing "Living Algorithms" for Real-Time Oncology Decision-Making](https://longbridge.com/en/news/286923155.md)
- [Chicago Concerned Citizens Call on City Council to Protect Small Businesses and Pursue Smarter Regulation of Prize and Gift Kiosks](https://longbridge.com/en/news/286834001.md)
- [Lipocine Showcases Phase 3 Data for Postpartum Depression](https://longbridge.com/en/news/286923466.md)